Lornamead To Settle With FTC Over Deceptive Lice-Prevention Claims
This article was originally published in The Rose Sheet
Firm lacks scientific evidence for the claim that its Lice Shield shampoo and spray products reduce risk of lice infestation by more than 80%, among other statements made in advertisements and on product labeling. Under the terms of a proposed settlement, Lornamead will pay $500,000 to FTC and refrain from using unsupported claims or misrepresenting tests, studies or research in the context of product marketing.
You may also be interested in...
SolRx petitions FDA to allow water-resistant sunscreen claims beyond the 80-minute cap established in the agency’s 2011 final rule. More news in brief.
FDA says it continues to consider the Personal Care Products Council’s 2011 petition requesting guidance regarding safe levels of lead in cosmetic products; Hong Kong-based firm Li & Fung Limited acquires Lornamead for $190 million. More new in brief.